Coverage
Filings
| Filing | Date |
|---|---|
| Director/PDMR Shareholding | 16 Oct 2024 |
| Positive results of ANCHOR trials of depemokimab | 14 Oct 2024 |
| Director/PDMR Shareholding | 14 Oct 2024 |
| Director/PDMR Shareholding | 11 Oct 2024 |
| Director/PDMR Shareholding | 10 Oct 2024 |
| Zantac (ranitidine) litigation settlements | 9 Oct 2024 |
| Positive efficacy data of Arexvy over 3 seasons | 8 Oct 2024 |
| Total Voting Rights | 1 Oct 2024 |
GSK said Monday it has appointed Chief Commercial Officer Luke Miels as its next chief executive, succeeding Dame Emma Walmsley.
GSK PLC announced plans to invest $30 billion in the United States over the next five years to boost its research, development, and manufacturing capabilities.
GSK said on Monday that the U.S. Food and Drug Administration has accepted for review its application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to at-risk adults aged 18 to 49.
| Positive EU opinion for GSK liquid Menveo vaccine |
| 24 Sept 2024 |
| Director/PDMR Shareholding | 24 Sept 2024 |
| Statement: Zantac (ranitidine) litigation | 18 Sept 2024 |
| Japan Filing Acceptance: Blenrep Multiple Myeloma | 17 Sept 2024 |